This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merali, S.
Right arrow Articles by Clarkson, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merali, S.
Right arrow Articles by Clarkson, A. B., Jr

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 07 1995, 1442-1444, Vol 39, No. 7
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine

S Merali, K Chin, RW Grady, L Weissberger and AB Clarkson Jr
Department of Medical and Molecular Parasitology, New York University School of Medicine, New York 10016, USA.

The iron-chelating drug deferoxamine mesylate (DFO) is active against Pneumocystis carinii in vitro and in rat and mouse models of P. carinii pneumonia. Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria. Therefore, results of single daily intraperitoneal injections were compared with results of an evenly divided four-times-daily dosage and the efficacy of delivery with implanted infusion pumps. The highest bolus dosage (1,000 mg kg-1 of body weight day-1) was as effective as the standard combination of trimethoprim with sulfamethoxazole. Unexpectedly, very little improvement was observed with the divided or continuous dosage, and several mechanisms that could account for this are discussed.


This article has been cited by other articles:

  • Moncada, C. A., Clarkson, A., Perez-leal, O., Merali, S. (2008). Mechanism and Tissue Specificity of Nicotine-mediated Lung S-Adenosylmethionine Reduction. J. Biol. Chem. 283: 7690-7696 [Abstract] [Full Text]  
  • Shivji, M., Burger, S., Moncada, C. A., Clarkson, A. B. Jr., Merali, S. (2005). Effect of Nicotine on Lung S-Adenosylmethionine and Development of Pneumocystis Pneumonia. J. Biol. Chem. 280: 15219-15228 [Abstract] [Full Text]  
  • Clarkson, A. B. Jr., Turkel-Parrella, D., Williams, J. H., Chen, L. C., Gordon, T., Merali, S. (2001). Action of Deferoxamine against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 3560-3565 [Abstract] [Full Text]  
  • Cirioni, O., Giacometti, A., Barchiesi, F., Scalise, G. (2000). Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46: 577-582 [Abstract] [Full Text]  
  • Merali, S., Vargas, D., Franklin, M., Clarkson, A. B. Jr. (2000). S-Adenosylmethionine and Pneumocystis carinii. J. Biol. Chem. 275: 14958-14963 [Abstract] [Full Text]  
  • Merali, S., Frevert, U., Williams, J. H., Chin, K., Bryan, R., Clarkson, A. B. Jr. (1999). Continuous axenic cultivation of Pneumocystis carinii. Proc. Natl. Acad. Sci. USA 96: 2402-2407 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»